{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T22:48:37Z","timestamp":1771627717386,"version":"3.50.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[1996,6]]},"abstract":"<jats:p>\n            <jats:italic>Abstract<\/jats:italic>\n            Amylin is a recently discovered peptide hormone composed of 37 amino acids that is cosecreted with insulin by pancreatic \u03b2 cells. Amylin has been reported to be present in increased amounts in insulin-resistant subjects who are hyperinsulinemic. Because blacks and whites differ in the prevalence of both hypertension and diabetes, we examined amylin levels in 77 individuals; 42 were black (11 hypertensive and 31 normotensive) and 35 were white (10 hypertensive and 25 normotensive) individuals who were either healthy control subjects or hypertensive subjects not receiving antihypertensive medication. Plasma amylin concentrations were measured in two separate monoclonal antibody\u2013based immunofluorescent sandwich-type assays. The F002-2 capture antibody binds amylin plus at least two additional amylin-like peptides, and the F024-4 capture antibody detectably binds only the amylin peptide. There was a significant race-by-diagnosis interaction for levels of amylin immunoreactivity during a 2-hour glucose tolerance test (\n            <jats:italic>P<\/jats:italic>\n            &lt;.005 for F002-2 antibody and\n            <jats:italic>P<\/jats:italic>\n            &lt;.05 for F024-4 antibody). Highest levels were found in black hypertensive subjects. The results appear to fit with previously observed differences in metabolic status between blacks and whites and with the association between hypertension and alterations in metabolic status.\n          <\/jats:p>","DOI":"10.1161\/01.hyp.27.6.1273","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T00:53:46Z","timestamp":1339462426000},"page":"1273-1276","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Effect of Race and Hypertension on Plasma Amylin Concentrations"],"prefix":"10.1161","volume":"27","author":[{"given":"Joel E.","family":"Dimsdale","sequence":"first","affiliation":[{"name":"From the Department of Psychiatry, University of California, San Diego (J.E.D., R.N.), and Amylin Pharmaceuticals, La Jolla, Calif (O.K., J.K.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orville","family":"Kolterman","sequence":"additional","affiliation":[{"name":"From the Department of Psychiatry, University of California, San Diego (J.E.D., R.N.), and Amylin Pharmaceuticals, La Jolla, Calif (O.K., J.K.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy","family":"Koda","sequence":"additional","affiliation":[{"name":"From the Department of Psychiatry, University of California, San Diego (J.E.D., R.N.), and Amylin Pharmaceuticals, La Jolla, Calif (O.K., J.K.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Nelesen","sequence":"additional","affiliation":[{"name":"From the Department of Psychiatry, University of California, San Diego (J.E.D., R.N.), and Amylin Pharmaceuticals, La Jolla, Calif (O.K., J.K.)."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(66)92132-5"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198708063170605"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199103143241105"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91904-6"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110572"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.30.3.219"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.430320205"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00404140"},{"key":"e_1_3_2_9_2","first-page":"414","volume":"127","year":"1987","unstructured":"Westermark P, Wernstedt C, O\u2019Brien TD, Hayden DW, Johnson KH. Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. Am J Pathol. 1987;127:414-417.","journal-title":"Am J Pathol"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.23.8628"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(91)90109-O"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.40.5.568"},{"key":"e_1_3_2_13_2","first-page":"A116","volume":"37","year":"1994","unstructured":"Wookey P, Berka J, Rumble J, Kelly D, Du H, Cooper M. Amylin binding sites in rat kidney and stimulation of plasma renin activity: characterization using antagonists. Diabetologia. 1994;37:A116. Abstract.","journal-title":"Diabetologia"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050092"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/dmr.5610060202"},{"key":"e_1_3_2_16_2","unstructured":"Hall WD Saunders E Shulman N eds. Hypertension in Blacks: Epidemiology Pathophysiology and Treatment. Chicago Ill: Year Book Medical Publishers Inc; 1985."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.12.2.115"},{"key":"e_1_3_2_18_2","first-page":"66","volume":"3","year":"1994","unstructured":"Rittenhouse J, Janes SM, Bierle JR, Park DM, Phelps JL, Koda JE. Isolation and characterization of human amylin. Protein Sci. 1994;3:66. Abstract.","journal-title":"Protein Sci"},{"key":"e_1_3_2_19_2","unstructured":"Percy AJ Trainor D Rittenhouse J Janes S Koda JE. Sensitive two-site enzyme immunoassays for amylin and amylin-like peptides in human plasma. Diabetologia. 1994;37(suppl 1):A117. Abstract."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.28.12.1039"},{"key":"e_1_3_2_21_2","unstructured":"Kailasam M Fineman M Koda J Parmer R O\u2019Connor D Circulating amylin in human essential hypertension: racial differences and early elevations in subjects at genetic risk of hypertension. J Invest Med. 1995;43(suppl 2):266A. Abstract."}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.HYP.27.6.1273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T17:09:46Z","timestamp":1715533786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.HYP.27.6.1273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1996,6]]}},"alternative-id":["10.1161\/01.HYP.27.6.1273"],"URL":"https:\/\/doi.org\/10.1161\/01.hyp.27.6.1273","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,6]]},"assertion":[{"value":"1995-11-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1996-02-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1996-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}